Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.
Read transcripts of webcasts and audiocasts
Read transcripts of webcasts and audiocasts
Disclaimer: This is a machine-generated transcript and may contain inaccuracies.
Good afternoon, and welcome to Revenio Group Q1 Earnings Call. My name is Jouni Toijala and I'm the group CFO for Revenio. And today we have a somewhat larger set of team members here. So, in addition to our usual CFO, Robin Pulkkinen, we also have Erkki Tala, Vice President, Products, on the call as well. And the reason for that is that we are going to run today a bit longer earnings call. So, of course, we are going to start with the Q1 financials and the business highlights. Then we go through the guidance part, which we do not have. But then we have a pretty extensive part run by Erkki. Regarding the Visionix transaction, especially related to the products and the product portfolio. But let's jump to Q1. So, reported net sales were 27.3 million. The increase on the reported side is 4.8%, with currency-adjusted net sales growth at 8.4%. So, I think it's a good number, especially taking into account the extremely strong start in the USA. So in terms of the euros, of course, but especially in terms of the US dollar, the organic growth in the USA was very, very strong. Then, other European countries were growing really strong as well. So especially France, UK and Germany. So in terms of the sales, good performance in the USA and in European countries. And then, we still had pretty tough comparables in the APAC region. So the APAC was slightly down. And if we look now, the start to Q2 in APAC. So we are also extremely well on track in APAC. As for sales, the operating profit was reported at 2.4 million. So significantly, of course, down. And of course, the main bucket there is roughly 3.1 million one-time costs related to the Visionix transactions. But Robin is going to cover these in more detail. So, from an adjusted operating profit perspective, it was good. The numbers, at 21.33% of sales, are, of course, slightly down from last year. But let's move to the financial part. So Robin, over to you. Thank you.
This typical graph, I think people are used to seeing, only covers the top line. Maybe also highlighting that the comparable Q1 25 FX adjusted growth was already close to 15%. So, we had a really tough comparable period ahead of us in Q1. So considering 8.4% FX adjusted growth, we feel it was a pretty good start in line with our plans for the year. The profitability did come down on the reported level, but it included one-time costs totaling 3.4 million. The 3.1 million of the transaction related costs. And then also some additional costs related to certain organizational changes we did still in the first quarter. Overall, the profitability drop is largely driven by the margin, which is much lower now than last year. We know that the tariffs are impacting that, but also the product mix, but we did now improve the gross margin from the last quarter of last year. As discussed, the price increases were not implemented by year-end. We have been now implementing those at the beginning of the year, so not fully effective for the whole quarter, but starting February, basically the price increases have been in the US. Adjusted operating profit. So that's probably the better line to look at the profitability. So 21.3% and 5.8 million. I'll come to the others in the coming slides, basically looking at the quarterly sales trend. As you covered, we did really well in the US and Europe. Basically, the FX was a significant headwind on the dollar versus euro. Basically, the change compared to the comparable period was that the euro was 11% stronger. So that is largely the impact that we have on the consolidated level when converting to the euro. So the US growth alone was actually very strong, as well as Europe APAC, as you said. We still continue to have some headwinds, but there were also some larger transactions in the comparable period which impacted the growth, but we were able to achieve it. So here are the profitability trend lines. So, here also reflecting the one-off costs and the organizational impacts we had, on the cost side, the FDA costs related to DRSplus and regulatory approvals in the US were actually probably a bit less than we expected. Those costs didn't really incur yet in the first quarter, but we are now expecting them to start accumulating more in the second quarter. And we see that patients are now starting to come into the clinics where we are doing the studies. Balance sheet remains unlevered for now. Everybody knows and has heard about the Visionix transaction. The equity ratio was still strong at the end of the first quarter. This is of course going to change as the transaction closes. As we've discussed earlier, the net debt to adjusted EBITDA is expected to decrease below 2.5. After the equity raise that we're planning to do in the fall. The leverage levels are going to be a lot higher at the closing, starting from the closing and then getting more to normalized levels. Once we do the rights issue in the fall. Basically, the equity ratio will probably be around 50% or slightly below by the end of the year. But now at the end of Q2, when we come out with our Q2 numbers, the balance sheet is going to be quite levered. Cash flow was not very strong in the first quarter. There were basically a couple of drivers; at the end of the year, you can see our Q4 was really strong. We had quite a lot of subcontracting or manufacturing in Italy. We have 90 days payment terms. We had quite big open invoices in the accounts payable at the end of the year. Those have now actually been paid in the first quarter. And also the revenue for the first quarter, it was very much March weighted. Well over 40% of the whole quarter's sales actually took place in March, which resulted in Accounts Receivable being quite abnormally high for this time of the year. Also, some tax payments were slightly higher than the previous year. The one that you can see is actually Danske Invest, number five. The one that you can see is actually the number five Danske Invest. They have appeared on the list now as a Finnish fund, I assume. The result is that the Finnish ownership actually also increased by roughly 1.5% during the quarter. For the guidance, we have now withdrawn the prior guidance. We are looking to come out after the transaction closes with an adjusted outlook for the year, but for now, for the coming weeks at least, we don't have any official guidance for investors. And then we have the AGM coming up. So if you remember, we cancelled the original AGM, which was planned to be held around mid-April. Now the new date is May 12th. There are a couple of changes to the original invitation that we sent out. So basically, in order to complete the transaction, we are asking the AGM to authorize the Board of Revenio to decide on a directed share issue for the sellers, which is part of the transaction payment, and also, asking for an authorization for the board to decide on issuance of shares in a planned 80 million Post-completion underwritten rights issue. Also, there are differences from the original invitation. We have three new board members that are being proposed. So the board is proposing the election of Charles Vilgrain, Marc Abitbol, and Nicklas Hansen to the Board of Directors of Revenio at the AGM on May 12th. And then also, just a note here that we have transaction support from the largest shareholder, William Demant Invest. So they have irrevocably undertaken to subscribe or vote. Sorry, sorry. Vote in favor of the proposals to the AGM. By the board or the or. By the board. Good.
Excellent. Before the Q&A, let's switch gears to the transaction, which was signed on April 13th. So, a couple of recap slides from me, and then we are actually going to go through in more detail. The products, product portfolio, and the overall logic. Why this deal very much makes sense for Revenio. But if we start from here, as I said, on April 13th, we joined forces. iCare. Visionix. And why this is remarkable. So we have been working in an addressable market, which represents roughly 1 billion in US dollars. So, we have been working on fundus imaging, perimetry, microperimetry, and tonometry. And by joining forces with Visionix, we are going to get an extremely comprehensive product portfolio. And we are able to increase the addressable market now from 1 billion to 2.5 billion USD. And why this is crucial for us also in the long term is that now we have a full suite of products for optometry, optical retail, and then of course, enhanced coverage on the ophthalmology side as well. But Jouni is going to come back to this one. And as a recap. So the deal was for €290 million, and the plan was really to finance it with cash reserves, then issuing Revenio shares to current main shareholders of Visionix at the price of €22.4. This is a significantly higher price than our shares are currently trading at. And then we have a debt financing plus the vendor loan. And then of course the rights issue, Robin is going to come back to this one. And in addition to this one, of course, we are expecting to have significant synergies coming from the sales side and also from the cost side in the coming years. And a couple of words regarding Visionix. So, the sales team, which generates roughly 150 million in net sales, is a global team. Even if it's said here that it's a French company. So, less than 200 people in France. And then if people are wondering that at Revenio, there are 250 people, Visionix has. There's a bit less than 600. So I think here we have to remember that Visionix operates directly. So sales directly in many countries. So it means more sales force than us. It means more customer service installations, etc. And of course, the assembly part of the business, which Visionix partly has in-house, is also a very good deal in terms of sales coverage. As everybody remembers, we have roughly 50% sales coming from the USA, then a bit more than 30% from Europe, Middle East, Africa, LATAM, and Canada, and then the remaining part from APAC. This deal will now effectively balance the regions. So the US sales come proportionally down. Then the EMEA increases and then we are getting more muscle also to APAC. But maybe we move the actual products now and the logic why this makes very much sense.
Thank you Jouni. Next, I will discuss the strategic rationale of the Visionix transaction from product and customer points of view, along with the opportunities this new combined portfolio opens for us in varying and actively evolving markets where one size doesn't fit all. I'll deepen the view of the impact of total addressable market and customer segments, and how expansion of them will open new avenues for our future growth. And all this will be combined with the evolutionary state of each market in terms of professional allocation of diagnostic tasks between optical retail, optometry, and ophthalmology. And this is really at the heart of the acquisition rationale, as it really explains the full market potential. So it's not only about having more products in more segments, but really having a coherent portfolio of products as a turnkey solution for different customer needs in different markets. And market conditions vary a lot based on regulatory or legal environment, professional education, and the role of different professional groups at the same time. And I will get back to that. In short, while many markets are going through significant evolution, especially in optical retail and clinical optometry, which means that as a result, many companies are increasingly adopting fundus imaging in optical retail. And now OCT technology is adopted very fast in optometric practices. And indeed, the value of getting OCT imaging into the portfolio will also be further explained in this presentation part. So let's start from this total addressable market expansion. As Jouni mentioned, our overall total addressable market expands from 1 billion USD to 2.5 billion USD a year. But from product portfolio point of view, this means that we will cover the entire diagnostic path from pretest to refraction, ophthalmic diagnostics, and disease monitoring. And while this is already good news. It's also crucial to understand what are those product categories we will not play in, even with a combined portfolio. And why? So, are we still missing something critical? In fact, the remaining market is largely related to surgical cataract care pathways, where the largest product segments are operating room microscopes and optical biometry. And these are very much used in surgical cataract ecosystems, which are typically relatively closed and would ideally require a proven intraocular lens portfolio. And this market has relatively high entry barriers. So we have made a clear strategic choice not to enter into these surgical settings, but stay in diagnostics. And this is a natural continuation for the strategic decision made already back in 2021 to focus fully on eye care and fully on ophthalmic diagnostics. That said, it's good to also have in mind that many general diagnostic modalities, from refraction to OCT, are also used with cataract patients too. So this means that we will cover almost all the product segments in this target market, excluding surgical cataract theater. If we then look at the customer segment expansion, that gives another important angle of view. Traditional customer segments for ophthalmic diagnostics companies are optical retail, optometry, and ophthalmology. And I have to say, most companies typically just cover some of them. But we will going forward cover them all. And also having a leading position on top of that in Microperimetry with our unique Maya device, servicing the strongly growing pharma research field, and, going forward, also the growing retina specialist segment. Additionally, we have also expanded to other healthcare, such as primary care and diabetes clinics, with our screening solution, combining the market's best screening fundus camera, iCare DRSplus, and a very well-performing AI algorithm, iCare RETCAD. This combo, as we have seen in the market, has clear, clear competitive advantage and has started to scale up well. So all in all, we can say that our customer segment coverage is the widest in the market when we combine these two companies together. Okay, let's move to a product portfolio then. So I've started by covering the overall total addressable market expansion as well as the market leading coverage in customer segments. So why does this combination matter? A few reasons. First of all, every single optical store, optometric practice, ophthalmology practice, or clinic needs refraction equipment, including Lensmeters, autorefractors, and refraction units. Secondly, in optical retail, ophthalmic diagnostics starts from tonometers and advances to fundus cameras. Many large optical retail markets are still in this transition phase, offering a great potential for future growth. And I'll get back to this market evolution a bit more in detail later. Thirdly, clinical optometry today demands ultra-wide field fundus imaging and increasingly OCT, typically as a combo. Now that we have these high-quality assets in the portfolio. This is really crucial to meet the needs of this segment, which is at the center of our business. And finally, ophthalmology. Ophthalmology uses OCT as a diagnostic standard in many cases already. And typically this is combined with a high-end fundus cameras. So we will have a broad portfolio of products meeting the needs of different customer segments. So we have called this a turnkey solution for optical retail and optometry. And this is what it really is. So a real turnkey solution can only be offered when the full clinical journey is covered by devices and solutions starting from pre-test phase or screening phase, as it shows here, to refraction and further to clinical diagnostics and disease management. And in our case, we will take the solution in optical retail until spectacle manufacturing by including finishing and dispensing devices in the portfolio. And beneath there you can see connecting platform and clinical data management as an underpinning connector. So, a connecting software platform is really key to build efficiencies in clinical workflows and collect data from multiple data points, supporting clinical decision making, often assisted nowadays by AI. So when patients and professionals are not always in the same location, electronic data transfer and tele optometry or teleophthalmology solutions are needed. And now these will also be included in our solution portfolio. We will combine these into a combined portfolio. All this together in a joint product portfolio and create a real one stop shop for many key customer segments. As I mentioned earlier, the optical retail and optometry landscape is really evolving fast. And I want to take a few example markets really kind of trying to explain this more deeply why different markets need really different recipe, different products to meet the customer needs. So there are still many markets, also very large ones like Italy. What I've used here as an example, where optical retail is focusing on refractive examinations and spectacle sales. Now with the full refraction product portfolio. We can fully tap into these markets as well. But there is at the same time, a clear trend that drives for larger adoption for clinical diagnostic tasks in optical retail and optometry, meaning that delegation of these tasks to better match increasing demand. And this is where Germany is used here as an example and is a good example of such a market. Such a market where optical retail is transforming towards early phase of clinical optometry services. This includes typically tonometry and fundus imaging. And this really offers great potential for us, as our combined refraction and clinical diagnostic device portfolio is in use. And we can see a nice uptake of such a solution already today. Then, as a third example here of different markets we operate in. I've got here US, UK and Australia, and there could be many other markets, where we have highly educated clinical optometry acting as a primary care for ophthalmic conditions. And in these markets, we offer a full end-to-end diagnostic solution, including advanced fundus imaging and OCT. So hopefully, this clarifies the strategic importance of the full end-to-end product portfolio. This is really the only way to be relevant in all the markets and be able to tap into opportunities in the current evolution when they open. And then about the OCT. So OCT has been probably the best recognized and mostly mentioned addition to Revenio's current portfolio via Visionix acquisition. And really it is an important part of it. But as I just explained, that's not the whole story. So with this transaction, we will get expedited entry to the OCT segment, which is really in many ways future proofing our portfolio. And I'll now bring three different dimensions to the importance of OCT. Of course, it is an interesting and important standalone business segment representing 700 million US dollar annual sales potential. And now we will get access to several sub-segments in that business and in that market with this transaction. So that's important. It's also equally, almost equally important to really have a solid solution for OCT, as OCT is really becoming a diagnostic imperative in ophthalmic diagnostics in different ways. And I'll open that a bit on the next slide. And thirdly, OCT is not only a standalone business. So it also, as a technology, offers us new opportunities for our product development, using the same technology across the different parts of the portfolio. So what does it mean that OCT is becoming a diagnostic imperative in ophthalmic diagnostics? A few words about OCT itself, what it is. You can imagine OCT being almost like an MRI of the eye. So really it is a non-invasive micron resolution cross-sectional study of the structures of the eye. And that means that it really expands diagnostic capabilities of fundus imaging to beneath the surface of the retina. It's not replacing fundus imaging, but it really increases the capabilities. And as such, it's an increasingly important tool for the diagnosis and management of common retinal and corneal diseases like AMD, diabetic retinopathy, glaucoma, and anterior segment conditions. And we also believe that there will be increased use for OCT technology going forward in retinal screening solutions as well. Then the role of the OCT as a driver for R&D and future R&D opportunities. So how does it help to develop other products? Our confocal imaging technology has really proven to have superior image quality in fundus imaging. And now we can explore the options to combine this with state-of-the-art combo devices. Fundus OCT combo devices are one of the fastest growing segments in the market. Besides that, for example, our MAIA micro perimeter, which is a gold standard in its segment, is an interesting area where OCT technology can be adopted. OCT technology will allow significant improvement opportunities for Perimetry and Microperimetry as well. So as an example, we have just released OCT-guided Microperimetry software module for MAIA. So, we are already acting in that space, and now we will have our own in-house OCT portfolio, technology, expertise, and knowledge to build on. So to sum up, the product and portfolio's rationale for this transaction involves three key areas or elements. So, a massive increase in total addressable market from 1 billion to 2.5 billion USD, covering the vast majority of the diagnostic equipment. We have decided to play in. And on top of that, we will cover all core customer segments in the market, resulting in the widest customer segment coverage, then allowing us to tap into opportunities in different markets that are in different evolutionary phases. And finally, of course, getting the important OCT addition into the portfolio and get that in a way that we will get three products straight into three subsegments in the market. So, having a great fast start and then really be able to adopt OCT technology into other product development as well going forward. So then.
So, just a reminder, I'll just cover again how the transaction is being financed. As you heard in the beginning, the enterprise value is EUR 290 million, from which the equity value is determined. 250 and 40 million for net debt, net working capital, and other adjustments define how it is allocated. Then, 22.3% of the 250 is being paid with shares. That adds up to 55.7 million. And the important point here is that the directed share issue to the sellers is done at a price of €22.40, which is roughly a 50% premium of where we are trading today. And the remaining 194.3 million is being paid with cash for financing it. We have the Nordea term loan facility, EUR 130 million, with very favorable terms from a shareholder point of view. We have the 80 million bridge-to-equity facility with a maturity of six plus six months. We have, of course, cash in hand, and we've agreed with Nordea on a revolving credit line, if needed. We have agreed with the sellers on a 17 million, roughly 10% of the cash portion, vendor loan interest-free, payable 12 months after closing. And with that, together with the directed issue, is how the transaction is being financed. The post completion rights issue for repaying the 80 million bridge loan that we've agreed with. Nordea is actually subject to decisions of the AGM, scheduled to be held on the 12th of May. In roughly a couple of weeks, Nordea has been engaged to act as the global coordinator and underwriter for the rights issue. The rights issue will be taking place sometime mid to late second half. So we need to be able to close Q2 for us to have fresh numbers. We will be preparing a full prospectus for the issue. William and the sellers, representing roughly 31% of the shares after post-completion, have irrevocably committed to subscribe pro-rata for the shares in the planned rights issue, and the remaining 69% is underwritten by Nordea. The financing is fully committed as it stands. Basically, as I said, the proceeds from the rights issue are being used to repay the bridge loan we have in the balance sheet. Good.
Okay, let's start recapping. Here you see the value creation journey. Three major parts. The first one is the quick wins mobilization. The second one is traction and build up. And then the third one is continued growth and sustained leadership on the product side. And if you start from the first one, so quick wins and mobilization. We have been working already months in order to be ready from day one after the closing. So we have a clear understanding regarding how the organizational operating model should function. And really, the plan right from the beginning is to have a clear target setting regarding the top-line synergies. We are identifying where to achieve top-line increases during 2026-2027 and where to realize cost synergies. So, actually, extremely good clarity for those plans is already in place and ready for day one. And then regarding the long-term synergies. So we are working and starting to work in detail regarding the portfolio product strategy, updating the combined company corporate strategy, and heading towards the CMD, which we are going to keep towards the end of September or early October. And as said earlier. So we are targeting to have a 20 million EBITDA uplift by the end of 29. Where 70% is planned to come by the end of 2027. Then if we move to the traction and build up part. Of course, we continue to harness the synergy plan. But then there's the big, big effort coming up. The plans are set to materialize already by the end of 2026, or early 2027. How the combined product roadmaps are going to look. So we see there great opportunities. And of course, all the time during 2026, 2027, and onwards, both companies are planning to continue to invest in R&D. So, as a standalone Revenio, in every segment where we are currently operating, we are going to have compelling products and software services coming out in the future. And the same, of course, applies for Visionix. And here we have said that by the end of 29, gradually, we are also going to get the profitability up to the levels where we currently operate and then beyond 2030. So, we also have clear ideas in mind; of course, we still need to work on how we are able to sustain the innovation for forthcoming products and what truly compelling and totally new we would be able to bring to the customers in the long run. And also, the plan is to start approaching from 25% EBITDA margin more towards 30%. And as I said, April 13th. The clear plan and target is that we are aiming to go three X faster than the market. So I think this is just good for everybody to keep in mind. But before moving to the Q&A, I bet there are quite many questions coming. So before jumping to that one, I would like to say a big thank you to Robin. So we have had a joint path together now, almost daily for six years. You have been working for Revenio for 11 years as of June, and when you joined, the company had about 30, 35, or 40 people. Right.
30. 32.
Yeah. And then, kind of divesting the portfolio, getting Visionix in, and now working on Visionix in order to open the next great path. So on my behalf, big thanks, Robin, for it has been a pleasure to work with you and good luck for the forthcoming job as well. So, and then of course, the good news is that we have been onboarding with Robin, already in place. So we have a continuation plan already in place and working well, but thank you Robin, and you are not released yet for sure. We have a Q&A coming. And I bet there are many, many questions coming, but do you have any final words of thanks?
I want to thank you. Everybody in the company, the colleagues and coworkers, of course, the investors and all the partners involved. It's been, I think, a great 11 years in the company. The difficult decision timing, maybe not optimal. These are the M&A, and changing jobs is a long process. And perhaps the timing wasn't ideal this time, but I feel that after 11 years in the company, it may be time to explore what else is available beyond Revenio. But I'm still joining another public company. So if you follow them, our paths might cross again.
Hey, good. Thank you. Robin. Let's move to the Q&A. I bet there are many questions coming, so let's address them all. Thank you.
If you wish to ask a question, please dial pound key five on your telephone keypad to enter the queue. If you wish to withdraw your question, please dial pound key six on your telephone keypad. The next question comes from Guglielmo Bruni Rocha from RBCCM. Please go ahead.
Hi. Thank you for taking my question. Just two from me. Could you update us on how the iCare ILLUME ramp is progressing? The last result you reported strong momentum in iCare ILLUME. So has this momentum continued? That concludes my first question, and now for my second question. You pointed to a very strong sales growth in the fundus device this quarter. So does this mean that we can expect a large increase in the Illume subscription through 2026 and next year as well? Thank you.
Regarding the momentum. So that's continuing. So we see increasing amounts of systems being deployed, with an increasing amount of, of course, hardware sold as part of the package. Part of the ILLUME package. We see increasing scaling up of the AI report package. And as said quite many times, of course, now the maturity of the revenue is coming from the device part, i.e., the DRSplus, but the overall take-up is good, and feedback is extremely good regarding the full end-to-end solution, then regarding the fundus imaging sales. So we saw a strong growth in the USA on the fundus imaging side. DRSplus is selling really well, of course. More sales on Europe level are driven by screening, whether it is ILLUME or just DRSplus, which is solely sold for screening. I think that hopefully that addresses your questions or anything else.
That's great. Thank you.
Thank you.
The next question comes from Nico Ruokangas from Seb. Please go ahead.
Hello, this is Nicolas from Seb. Thank you for the presentation. And first of all thank you Robin for the years and good luck for the future.
Thank you.
I have a couple of questions and I'd like to start also on the financial side of old Revenio business. Could you comment on what kind of markets you have seen? They're improving. Or do you think that you are taking market share there, given that some of your competitors seem to be struggling in the segment?
Regarding Q1, I think we haven't yet seen the comp numbers. So I think coming most probably in 1 to 3 weeks' time, it's hard to comment on that one, but I think if the normal market, when it's normal, on the fundus imaging side grows roughly 3% or so forth. So for sure, we have had higher growth, but I think we'll know in a couple of weeks' time when we know the competitors' numbers, but for us, products have been moving out really, really well. And especially even when looking from the US dollar perspective. Growth from a U.S. dollar perspective, which compares apples to apples. We experienced good growth during Q1.
That's good to hear. And is this kind of a sales mix for the old Revenio? with higher now. Fundus imaging taking higher shares? Or is this something you expect to see also in the coming quarters?
For the whole year, I think we've planned a growth also for Tonometers. But now imaging did take a very strong start for the year. We do have very promising deals on the imaging side, especially on the pipeline. So there's a good chance that it does perform quite well this year. It's difficult to say yet, but I think Q1 was a bit stronger than we expected. A couple quarters ago.
Okay. Thank you. Then moving on to Visionix. And I was wondering whether you could give us some comments on Visionix performance in Q1, as you probably know how they have been doing. And then maybe, additionally, as you just talked about different product categories you are entering now through the acquisition. So, could you give us some further color on which product segments within Visionix have been growing and which have not during the past couple of years?
So, do you want to go ahead? So maybe I comment, so we signed the deal April 13th. We haven't closed the deal. So we don't have a possibility to comment on their behalf. Their performance as such, perhaps a general comment regarding the different segments they have. So, from the market study perspective, an overall industry trend perspective, it's fair to assume that OCT is from the ophthalmic diagnostic device market perspective. So that's estimated to grow quite fast. 4.7% roughly, as Erkki was mentioning. I think it's a fair assumption also from their side that it's a growing segment. And then of course, the multimodal devices, which were really core of our strategy. If you go back to the last Capital Markets Day. We were highlighting the multimodal growth. That's really a growing segment where Visionix is having a unique product. So in that perspective, I think they are good on that side as well. And of course, the software solutions. So, coming back to the telehealth, what Erkki mentioned, telehealth is increasing in terms of demand as well. So, but, Nico, sorry, not able to before the closing answer on their behalf.
Yeah, I understand, but that's good. Thank you. Then the last one from me at this point, you are targeting for the combined company three times market growth and an EBITDA margin of 25% in 2028-2029. My question is, how tightly are these two targets – growth and profitability – connected? How high combined sales do you need to have in your estimates so that you would reach 25% EBITDA margin?
If we consider the logic, we have been communicating to the market our targets. The target is to grow three X faster than the market. Throughout all these years, whether it is 2027, 2028, 2029, or 2030. That's our aim to grow three times faster than the market. And then the second topic is which we envision to improve quarter by quarter. Year by year, we envision hitting the 25% EBITDA margin by the end of 2025. So sorry. Yeah, yeah. 2028. So that's in a planning book for us. So, gradually bringing the profitability up and then, of course, keeping the sales growth up as well during the years and coming quarters.
Yeah. Growth, we need growth also to cover, of course, the cost base continues to grow with inflation. So it is difficult without growth to achieve all these profitability targets, as I'm sure you understand.
Yes. Thank you. That's all from me. Thank you.
Thank you Nicole.
The next question comes from Daniel Lepisto from Danske Bank. Please go ahead.
Hi, it's Daniel from Danske Bank. Thanks for the comprehensive presentation. I also have a couple of questions, maybe starting off with this gross margin, which remains below 70%, which is not something that we used to seeing for you guys for a prolonged period. So how much was the FX impact here? And with these tariffs in place, do you think this is the new normal? Can you do anything here if this current tariff regime remains in place? Can you do more price hikes or are you fighting towards the 70% level? For now.
I think we're probably targeting to get closer to 70. So the price increases weren't fully in for the whole quarter. So we expect to do a little bit better. Then of course, the imaging sales proportion was quite high in Q1, which also has an impact on the gross margin as their gross margin is a little bit lower, but the price increases were not fully in yet for the whole quarter. So, the tariffs definitely have an impact. So we're targeting to make as many euros as before. But the price increases, prompted by the tariffs, are just covering the cost increase with zero margin. So the percentage mathematically comes down, even though the euros are still being covered by the price increases.
And the comparable quarter, Q1 2025. So there was no tariff impact as well. And that was the reason why the gross margin was over 72%. Yeah.
Yeah. Of course, FX has an impact because, compared to last year's exchange rates, the same amount of dollars would have yielded 11% more in top line revenue. So basically that of course has an impact on the gross margin. We do have roughly 25 to 30% of our cost of sales priced in dollars. So it's not that there's a significant buffer or robust hedging in place, but there's a considerable impact on the gross margin and EBIT level as well.
All right. Thank you. Okay. Maybe continuing on this, still on the segment-level growth that you discussed, specifically about fundus imaging growing very strongly. So, along with how you typically guide verbally on these growth rates, how does this tally up with tonometers, probes, and perimeters growing since, with 8% growth and imaging devices growing very strongly, it seems that something is not growing or is barely growing. If we look at the full product segments. So can you comment on these other segments? How are they growing?
The biggest reason for the poor growth was the poor performance in APAC. So, basically, that pulled down overall results, even though Europe and the US were performing extremely well. But then APAC was clearly down, and one driver there was the comparable period. We had a pretty big, one-time order that we didn't get this year. So looking at Q2, we don't have that big order in the comparables in APAC. So, it is expected to improve.
Okay. That's clear. Maybe a final question on these larger deals in the pipeline that you have been talking about, I guess since Q3 last year. So there seems to be a quite long lead time. So these have been noted as material, with a potential impact on the guidance. So these are still on the table, or you haven't fully approved of them quite yet.
They're still working on it. Not the fastest to close, apparently.
All right. That's good. That's all from me. Thank you.
Thank you Danielle.
As a reminder, if you wish to ask a question, please dial pound key five on your telephone keypad. The next question comes from Pierre Salameh from DMB Carnegie. Please go ahead.
Hi gentlemen, it's Pierre from D and B Carnegie. Thank you for taking my questions. I'll start by acknowledging that you have withdrawn your guidance, but can you give some comments based on the performance you now saw in Q1? Are you tracking along the lower end of that guided range? So I think you alluded to that everything has proceeded according to your plans. But maybe coming back to Danielle's comment. So how comfortable are you that your portfolio will continue to perform in the same way?
I think, looking at last year's quarters, we had the toughest comparison quarter or the biggest growth quarter. Q1 grew last year almost 15%. So internally, our plans also were expecting the Q1 to be the lower growth quarter out of the four. So in a way, it's fully in line with what we've been planning to do.
All right. Thanks. Then, regarding the clinical trial. You said you are now in the phase of recruiting, or the patients are entering the clinics. What kind of costs should we expect related to the clinical trials? Now, for the remaining quarters of 2026.
The pre-study expense estimation was like six hundred to seven hundred thousand. We did incur some of that already. But there is probably, I'd say, maybe 400,000 to 500,000 left. Or do you have a better estimate?
That's a ballpark, right? Yes. Yeah, yeah.
All right. Okay. Thank you. Then, going to the Visionix deal. My first question is, what kind of terms and conditions do you have? Is there a risk that the deal falls through? Now, given that your share price has declined clearly since the announcement?
No. No. We are proceeding as planned. There are no such provisions. No triggers related to the share price of any type.
All right. Uh, good. Thanks. And then, regarding Visionix, you published sales and earnings numbers for 24 and 25. And the market saw that the company hasn't been growing. So, can you shed some light regarding the organic growth of that business going back several years, like 4 or 5 years would be really helpful to get an understanding of how their business has been able to grow.
So if we go back to a longer period, roughly nine or ten years or so forth. So, they have had a stronger growth, roughly 8%. They have been able to grow. And now when looking at the combined company. So we are extremely sure that we are able to get the combined company and also their product portfolio growing. Otherwise, we wouldn't, of course, have closed the transaction, and we are extremely sure that we are able to get the profitability up as well. So we have a clear plan for that. And they have clear plans already. And that has already improved, even during Q1.
I think Mark said that when we released the transaction, or during the analyst visit and presentations related to the announcement. I think Marc said that, like us, the Covid years were very strong for them. So they're similar to us. They were growing very strongly in the beginning of the 2020s, just like we were.
All right. Thank you. And maybe still regarding the expectations, looking forward for Visionix, they did not grow last year, but profitability improved on EBITDA level. And the margin improved. So, can you shed any light on your expectations for Visionix this year?
For this year, I can't really disclose what the outlook is. I think we're going to come back to that then with the combined guidance. And then I'm sure in the Capital Markets Day. And then for the rights issue, we need to do the full prospectus. So that will be a lot of valuable information for investors to look into, but unable to comment at this stage.
Yeah. All right. Thank you. And then finally, when I, as an outsider and not an ophthalmic specialist, look at the portfolio of the combined company, the question that appears is: is this finishing and dispensing business? Is it really core for you from a diagnostic perspective?
It's obviously not part of diagnostic pathway, but it's still part of the, let's say, customer journey, especially in optical retail, which is a kind of strong segment for Visionix. So they are serving a lot of those customers in that segment who are still also manufacturing spectacles inside optical retail stores. So, not really part of the clinical journey, but part of the customer journey.
All right. All right. That's all for me. Thank you so much. And thank you, Robin, for excellent cooperation. Cooperation during the past years.
Thank you.
Thank you Pierre.
There are no more questions at this time. So I hand the conference back to the speakers for any closing comments.
Okay. Thank you all. Have a good springtime. And we will return with an update on the combined company. Q2 numbers. And now heading towards the closing of the transaction. And thank you for participating. And thank you for the really good questions.



















